🟠 Moderate Evidence
A novel vaccine combining protection against both Lassa fever and rabies has demonstrated safety and immunogenicity in its first human trial. The phase 1 study, published in Nature Medicine, tested an adjuvanted inactivated rabies virus-vectored Lassa virus vaccine (LASSARAB + 3D-6-acyl PHAD-SE) in healthy adults. This represents a significant milestone in developing protection against Lassa fever, a viral hemorrhagic fever that affects up to 300,000 people annually in West Africa.
Key takeaways
- First-in-human trial shows dual rabies-Lassa fever vaccine is safe in healthy adults
- Vaccine induced immune responses to both Lassa virus and rabies virus
- Study marks major progress toward protecting against deadly hemorrhagic fever
Study at a Glance
| Source | Nature Medicine |
| Study type | Phase 1 clinical trial |
| Sample size | Healthy adults (specific N not disclosed in interim report) |
| Population | Healthy adult volunteers |
| Country | Not specified in interim report |
Lassa Fever Burden in West Africa
Annual cases and mortality in endemic regions
Source: World Health Organization, 2026 | Georgian Medical Journal News
Breakthrough in Hemorrhagic Fever Prevention
The LASSARAB vaccine represents a novel approach to preventing Lassa fever, using an inactivated rabies virus as a vector to deliver Lassa virus antigens. According to the Nature Medicine interim report, the combination vaccine successfully induced immune responses against both pathogens in healthy participants.
Lassa fever, caused by the Lassa virus, is endemic across West Africa and poses significant public health challenges. The World Health Organization estimates that 10-16% of people in some areas of Sierra Leone and Liberia are infected annually, with the virus responsible for 10-16% of total admissions to hospitals in the region.
The vaccine’s dual-target design offers potential advantages for regions where both rabies and Lassa fever are endemic. This approach could streamline vaccination programs while providing broader protection against two serious viral diseases that disproportionately affect resource-limited settings.
Safety Profile Encourages Further Development
The phase 1 trial’s interim safety data represents crucial progress for Lassa fever vaccine development. Previous attempts to develop effective vaccines against Lassa virus have faced significant challenges, making this safety milestone particularly noteworthy for the global health community.
The adjuvant 3D-6-acyl PHAD-SE, combined with the inactivated rabies-vectored approach, appears to enhance immune responses without compromising safety profiles. This formulation strategy builds on decades of rabies vaccine safety data while introducing novel Lassa virus protection, according to the study published in peer-reviewed research.
Researchers noted that the vaccine’s immunogenicity against both target viruses suggests the platform could be viable for broader implementation, pending successful completion of larger trials and regulatory review processes.
Addressing Critical Global Health Gap
Lassa fever remains one of several viral hemorrhagic fevers lacking effective vaccines, creating vulnerability for millions across West Africa. The Centers for Disease Control and Prevention recognizes Lassa fever as a priority pathogen due to its epidemic potential and limited therapeutic options.
The disease typically presents with fever, weakness, and malaise, but can progress to severe complications including bleeding, respiratory distress, and multi-organ failure. Early diagnosis and supportive care remain the primary interventions, with ribavirin showing limited efficacy when administered early in infection.
This vaccine development comes as part of broader global health initiatives to prepare for emerging infectious diseases. The Coalition for Epidemic Preparedness Innovations (CEPI) and similar organizations have prioritized development of vaccines against pathogens with pandemic potential, including Lassa virus and other hemorrhagic fever viruses covered in global health research.
Next Steps and Regulatory Pathway
The promising phase 1 results position the LASSARAB vaccine for advancement to phase 2 trials, which will evaluate efficacy and safety in larger, more diverse populations. Future studies will need to demonstrate not only immunogenicity but also clinical protection against Lassa fever infection.
Regulatory pathways for Lassa fever vaccines may benefit from expedited review processes given the unmet medical need and limited therapeutic alternatives. The FDA’s breakthrough therapy designation and similar pathways could accelerate development timelines for effective vaccines.
Manufacturing scalability and distribution logistics will present additional challenges, particularly for reaching endemic regions with limited cold-chain infrastructure. However, the combination approach with rabies vaccination could leverage existing immunization programs and infrastructure in affected areas.
The adjuvanted inactivated rabies virus-vectored Lassa virus vaccine demonstrated safety and induced immunogenicity to both Lassa and rabies viruses in healthy participants during phase 1 testing.
— Research team, Nature Medicine interim report (2026)
What this means
Frequently asked questions
What is Lassa fever and how dangerous is it?
Lassa fever is a viral hemorrhagic fever caused by Lassa virus, endemic in West Africa. According to WHO data, it affects up to 300,000 people annually with a case fatality rate of 1-2% overall, but can reach 15-20% in hospitalized patients.
How does this vaccine work?
The LASSARAB vaccine uses inactivated rabies virus as a vector to deliver Lassa virus antigens, creating immune responses against both diseases. The adjuvant 3D-6-acyl PHAD-SE enhances the immune response.
When might this vaccine become available?
The vaccine is still in early clinical development following phase 1 trials. It will require successful phase 2 and phase 3 trials, plus regulatory approval, before becoming widely available – a process typically taking several years.
The successful phase 1 trial of the LASSARAB vaccine marks a critical step forward in addressing one of West Africa’s most significant infectious disease challenges. As the vaccine advances through clinical development, it offers hope for reducing the substantial burden of Lassa fever while simultaneously providing rabies protection in regions where both diseases pose ongoing threats to public health.
Source: Adjuvanted inactivated rabies virus-vectored Lassa virus vaccine in healthy adults: a phase 1 trial
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
